Europe Angiogenesis Modulators Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Angiogenesis Modulators Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Angiogenesis Inhibitors Market Performance (Volume)
  • 2.1.2 Angiogenesis Stimulators Market Performance (Volume)
  • 2.1.3 Angiogenin Market Performance (Volume)
  • 2.1.4 Others Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Angiogenesis Inhibitors Market Performance (Value)
  • 2.1.2 Angiogenesis Stimulators Market Performance (Value)
  • 2.1.3 Angiogenin Market Performance (Value)
  • 2.1.4 Others Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Breast Cancer Market Performance (Volume)
  • 3.1.2 Colorectal Cancer Market Performance (Volume)
  • 3.1.3 Lung Cancer Market Performance (Volume)
  • 3.1.4 Prostate Cancer Market Performance (Volume)
  • 3.1.5 Others Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Celgene Corporation (USA)
  • 4.1.1 Celgene Corporation (USA) Profiles
  • 4.1.2 Celgene Corporation (USA) Product Information
  • 4.1.3 Celgene Corporation (USA) Angiogenesis Modulators Business Performance
  • 4.1.4 Celgene Corporation (USA) Angiogenesis Modulators Business Development and Market Status
• 4.2 Eisai Co., Ltd. (Japan)
  • 4.2.1 Eisai Co., Ltd. (Japan) Profiles
  • 4.2.2 Eisai Co., Ltd. (Japan) Product Information
  • 4.2.3 Eisai Co., Ltd. (Japan) Angiogenesis Modulators Business Performance
  • 4.2.4 Eisai Co., Ltd. (Japan) Angiogenesis Modulators Business Development and Market Status
• 4.3 Amgen, Inc. (USA)
  • 4.3.1 Amgen, Inc. (USA) Profiles
  • 4.3.2 Amgen, Inc. (USA) Product Information
  • 4.3.3 Amgen, Inc. (USA) Angiogenesis Modulators Business Performance
  • 4.3.4 Amgen, Inc. (USA) Angiogenesis Modulators Business Development and Market Status
• 4.4 Genentech, Inc. (USA)
  • 4.4.1 Genentech, Inc. (USA) Profiles
  • 4.4.2 Genentech, Inc. (USA) Product Information
  • 4.4.3 Genentech, Inc. (USA) Angiogenesis Modulators Business Performance
  • 4.4.4 Genentech, Inc. (USA) Angiogenesis Modulators Business Development and Market Status
• 4.5 GlaxoSmithKline plc (UK)
  • 4.5.1 GlaxoSmithKline plc (UK) Profiles
  • 4.5.2 GlaxoSmithKline plc (UK) Product Information
  • 4.5.3 GlaxoSmithKline plc (UK) Angiogenesis Modulators Business Performance
  • 4.5.4 GlaxoSmithKline plc (UK) Angiogenesis Modulators Business Development and Market Status
• 4.6 Bayer Pharma AG (Germany)
  • 4.6.1 Bayer Pharma AG (Germany) Profiles
  • 4.6.2 Bayer Pharma AG (Germany) Product Information
  • 4.6.3 Bayer Pharma AG (Germany) Angiogenesis Modulators Business Performance
  • 4.6.4 Bayer Pharma AG (Germany) Angiogenesis Modulators Business Development and Market Status
• 4.7 Bionomics Ltd. (Australia)
  • 4.7.1 Bionomics Ltd. (Australia) Profiles
  • 4.7.2 Bionomics Ltd. (Australia) Product Information
  • 4.7.3 Bionomics Ltd. (Australia) Angiogenesis Modulators Business Performance
  • 4.7.4 Bionomics Ltd. (Australia) Angiogenesis Modulators Business Development and Market Status
• 4.8 CASI Pharmaceuticals, Inc. (USA)
  • 4.8.1 CASI Pharmaceuticals, Inc. (USA) Profiles
  • 4.8.2 CASI Pharmaceuticals, Inc. (USA) Product Information
  • 4.8.3 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Business Performance
  • 4.8.4 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Business Development and Market Status
• 4.9 AstraZeneca plc (UK)
  • 4.9.1 AstraZeneca plc (UK) Profiles
  • 4.9.2 AstraZeneca plc (UK) Product Information
  • 4.9.3 AstraZeneca plc (UK) Angiogenesis Modulators Business Performance
  • 4.9.4 AstraZeneca plc (UK) Angiogenesis Modulators Business Development and Market Status
• 4.10 Eli Lilly and Company (USA)
  • 4.10.1 Eli Lilly and Company (USA) Profiles
  • 4.10.2 Eli Lilly and Company (USA) Product Information
  • 4.10.3 Eli Lilly and Company (USA) Angiogenesis Modulators Business Performance
  • 4.10.4 Eli Lilly and Company (USA) Angiogenesis Modulators Business Development and Market Status
• 4.11 F.Hoffmann-La Roche AG (Switzerland)

5 Market Performance for Manufacturers

• 5.1 Europe Angiogenesis Modulators Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Europe Angiogenesis Modulators Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 Europe Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 Europe Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 Germany Market Performance for Manufacturers
  • 6.1.1 Germany Angiogenesis Modulators Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 Germany Angiogenesis Modulators Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 Germany Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 Germany Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 UK Market Performance for Manufacturers
  • 6.2.1 UK Angiogenesis Modulators Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 UK Angiogenesis Modulators Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 UK Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 UK Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 France Market Performance for Manufacturers
  • 6.3.1 France Angiogenesis Modulators Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 France Angiogenesis Modulators Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 France Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 France Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Russia Market Performance for Manufacturers
  • 6.4.1 Russia Angiogenesis Modulators Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Russia Angiogenesis Modulators Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Russia Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Russia Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 Benelux Market Performance for Manufacturers
  • 6.5.1 Benelux Angiogenesis Modulators Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 Benelux Angiogenesis Modulators Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 Benelux Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 Benelux Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 Italy Market Performance for Manufacturers
  • 6.6.1 Italy Angiogenesis Modulators Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 Italy Angiogenesis Modulators Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 Italy Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 Italy Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Spain Market Performance for Manufacturers
  • 6.7.1 Spain Angiogenesis Modulators Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Spain Angiogenesis Modulators Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Spain Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Spain Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 Market Performance for Manufacturers
  • 6.8.1 Angiogenesis Modulators Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 Angiogenesis Modulators Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 Angiogenesis Modulators Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 Angiogenesis Modulators Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Europe Angiogenesis Modulators Market Performance (Sales Point)

• 7.1 Europe Angiogenesis Modulators Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 Europe Angiogenesis Modulators Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 Europe Angiogenesis Modulators Price (USD/Unit) by Regions 2013-2018
• 7.4 Europe Angiogenesis Modulators Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Europe Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 Germany Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 UK Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 France Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Russia Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 Benelux Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 Italy Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Angiogenesis Modulators Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Breast Cancer Industry
• 11.2 Colorectal Cancer Industry
• 11.3 Lung Cancer Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 Europe Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 Europe Angiogenesis Modulators Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 Germany Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 UK Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 France Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Russia Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 Benelux Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Italy Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Spain Angiogenesis Modulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Angiogenesis Inhibitors Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Angiogenesis Stimulators Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 Angiogenin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.5 Others Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Breast Cancer Sales and and Growth Rate 2019-2024
  • 12.4.3 Colorectal Cancer Sales and and Growth Rate 2019-2024
  • 12.4.4 Lung Cancer Sales and and Growth Rate 2019-2024
  • 12.4.5 Prostate Cancer Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 Europe Angiogenesis Modulators Price (USD/Unit) Trend 2019-2024
  • 12.5.2 Europe Angiogenesis Modulators Gross Profit Trend 2019-2024

13 Conclusion